CGRP Receptor Modulators in Neurodegeneration

Migration, Crosslink

📖

CGRP Receptor Modulators in Neurodegeneration

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-cgrp-receptor-modulato

📖 Wiki Page

therapeutic1965 wordssynced 2026-04-02

CGRP Receptor Modulators in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CGRP Receptor Modulators in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Peptide</td>
<td>Primary Expression</td>
</tr>
<tr>
<td class="label">α-CGRP</td>
<td>Sensory neurons, CNS neurons</td>
</tr>
<tr>
<td class="label">β-CGRP</td>
<td>Enteric nervous system</td>
</tr>
<tr>
<td class="label">Amylin</td>
<td>Pancreatic beta cells</td>
</tr>
<tr>
<td class="label">Adrenomedullin</td>
<td>Endothelial cells, adrenal medulla</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Erenumab (Aimovig)</td>
<td>CGRP receptor (CLR/RAMP1)</td>
</tr>
<tr>
<td class="label">Fremanezumab (Ajovy)</td>
<td>CGRP ligand</td>
</tr>
<tr>
<td class="label">Galcanezumab (Emgality)</td>
<td>CGRP ligand</td>
</tr>
<tr>
<td class="label">Eptinezumab (Vyepti)</td>
<td>CGRP ligand</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rimegepant (Nurtec ODT)</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Atogepant (Qulipta)</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Ubrogepant (Ubrelvy)</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Zavegepant (Zavzpret)</td>
<td>CGRP receptor anta

...

CGRP Receptor Modulators in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CGRP Receptor Modulators in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Peptide</td>
<td>Primary Expression</td>
</tr>
<tr>
<td class="label">α-CGRP</td>
<td>Sensory neurons, CNS neurons</td>
</tr>
<tr>
<td class="label">β-CGRP</td>
<td>Enteric nervous system</td>
</tr>
<tr>
<td class="label">Amylin</td>
<td>Pancreatic beta cells</td>
</tr>
<tr>
<td class="label">Adrenomedullin</td>
<td>Endothelial cells, adrenal medulla</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Erenumab (Aimovig)</td>
<td>CGRP receptor (CLR/RAMP1)</td>
</tr>
<tr>
<td class="label">Fremanezumab (Ajovy)</td>
<td>CGRP ligand</td>
</tr>
<tr>
<td class="label">Galcanezumab (Emgality)</td>
<td>CGRP ligand</td>
</tr>
<tr>
<td class="label">Eptinezumab (Vyepti)</td>
<td>CGRP ligand</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Rimegepant (Nurtec ODT)</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Atogepant (Qulipta)</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Ubrogepant (Ubrelvy)</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Zavegepant (Zavzpret)</td>
<td>CGRP receptor antagonist</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">AD neuroinflammation</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">PD trigeminovascular</td>
<td>Preliminary</td>
</tr>
<tr>
<td class="label">ALS motor neurons</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Neurovascular coupling</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Therapeutic translation</td>
<td>Early</td>
</tr>
</table>

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide that functions as one of the most potent vasodilators in the human body and serves as a critical mediator of neurogenic inflammation. The CGRP signaling pathway has emerged as a significant therapeutic target across neurodegenerative diseases, including [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS), and [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD)[@yuan2019][@walker2020].

CGRP is predominantly expressed in sensory neurons of the trigeminal and dorsal root ganglia, with widespread distribution throughout the central and peripheral nervous systems. Its receptors are expressed on neurons, glial cells (microglia and astrocytes), vascular smooth muscle, and immune cells including mast cells and macrophages. This broad distribution underlies CGRP's diverse roles in pain transmission, neurovascular coupling, neuroinflammation, and cellular stress responses — all processes central to neurodegeneration[@ruscheweyh2021][@edvinsson2023].

CGRP Biology

CGRP Peptide Family

CGRP belongs to a family of structurally related peptides:

CGRP Receptor Complex

The canonical CGRP receptor is a heterodimeric complex[@miller2020]:

CLR (Calcitonin receptor-like receptor): 7-transmembrane G protein-coupled receptor, provides ligand-binding specificity
RAMP1 (Receptor activity-modifying protein 1): Accessory protein required for CGRP binding; determines receptor trafficking to cell surface
RCP (Receptor component protein): Intracellular protein that couples the receptor to Gαs signaling

Signaling pathways activated by CGRP:

cAMP/PKA pathway: Primary signaling via Gαs activation and adenylate cyclase stimulation
MAPK/ERK pathway: Involved in gene transcription and cell survival
PI3K/AKT pathway: Neuroprotective signaling cascades
NF-κB pathway: Pro-inflammatory gene expression

CGRP Distribution in the Brain

CGRP is widely distributed in regions critical to neurodegenerative disease:

Cortex and hippocampus: High concentrations in pyramidal neurons; modulates synaptic plasticity
Substantia nigra: CGRP-containing neurons; potential role in PD
Spinal cord: Primary afferent terminals carrying pain and sensory signals
Cerebral blood vessels: Perivascular nerve endings; regulates cerebral blood flow
Dorsal root ganglia: Sensory neuron cell bodies; pain and proprioception

CGRP in Alzheimer's Disease

Evidence of CGRP Involvement

Multiple studies have documented altered CGRP levels and signaling in Alzheimer's disease[@bhatt2020][@topham2022]:

Elevated CSF CGRP: Studies consistently report increased CGRP levels in the cerebrospinal fluid of AD patients compared to healthy controls, correlating with disease severity and cognitive decline
CGRP and amyloid pathology: CGRP receptor activation promotes amyloid-beta production through Gs-coupled signaling pathways, potentially accelerating plaque formation
Microglial modulation: CGRP acting through microglial CGRP receptors promotes a pro-inflammatory phenotype, increasing TNF-α, IL-1β, and IL-6 release

Mechanistic Pathways

Mermaid diagram (expand to render)

CGRP-Microglial Cross-Talk

CGRP acts on microglia through CGRP receptor expression on these cells[@topham2022]:

M1-like polarization: CGRP promotes microglial differentiation toward pro-inflammatory M1 phenotype
NF-κB activation: CGRP stimulates IKK complex, releasing NF-κB for nuclear translocation
Inflammasome activation: NLRP3 inflammasome activation in response to CGRP signaling
Neurotoxic factor release: Microglia stimulated by CGRP release glutamate, ROS, andnitric oxide

Therapeutic Implications in AD

CGRP receptor modulators may benefit AD through:

Reducing neuroinflammation: Blocking CGRP signaling shifts microglia toward anti-inflammatory M2 phenotype

Improving cerebral blood flow: CGRP antagonists restore neurovascular coupling and cerebral perfusion

Modulating amyloid processing: Reduced cAMP signaling may decrease amyloidogenic APP processing

Neuroprotection: Blocking excessive CGRP signaling may prevent excitotoxic mechanisms

CGRP in Parkinson's Disease

Trigeminovascular System in PD

The trigeminovascular system, which uses CGRP as its primary neurotransmitter, has been implicated in Parkinson's disease pathology[@Gonzalez-Reyes LE]:

Trigeminal nerve involvement: PD patients show increased trigeminal pain sensitivity and altered blink reflexes
Neurogenic inflammation: CGRP release from trigeminal neurons triggers meningeal inflammation, potentially contributing to non-motor symptoms
Alpha-synuclein connection: CGRP-positive neurons in the locus coeruleus may be vulnerable to alpha-synuclein pathology

CGRP and Neuroinflammation in PD

CGRP contributes to neuroinflammation in PD through multiple mechanisms:

Microglial activation: CGRP receptor on microglia promotes activation and cytokine release
Peripheral immune infiltration: CGRP-mediated blood-brain barrier permeability may facilitate immune cell entry
Enteric nervous system: CGRP in the gut may modulate intestinal inflammation associated with PD prodrome

Clinical Observations

Migraine-PD association: Epidemiological studies suggest increased PD risk in migraine patients with aura
CGRP in PD CSF: Preliminary studies indicate altered CGRP levels in PD patient CSF
L-dopa and CGRP: Levodopa treatment may influence CGRP dynamics in PD patients

CGRP in ALS

CGRP in Motor Neuron Vulnerability

Motor neurons show particularly high CGRP expression, and CGRP pathways may contribute to ALS pathophysiology:

Motor neuron CGRP: Motoneurons express high levels of CGRP and its receptor, suggesting autocrine signaling
Excitotoxicity connection: CGRP signaling through cAMP may synergize with glutamate-mediated excitotoxicity
Neurotrophic factor interactions: CGRP can modulate BDNF and GDNF signaling pathways

CGRP and Inflammation in ALS

Mast cell activation: CGRP activates mast cells, which are increasingly recognized in ALS neuroinflammation
Vascular permeability: CGRP-mediated blood-spinal cord barrier alterations may facilitate immune infiltration

CGRP in Frontotemporal Dementia

Emerging evidence links CGRP to FTD pathophysiology:

TDP-43 pathology: CGRP neurons may be particularly vulnerable to TDP-43 aggregation
Neuroinflammation: Similar mechanisms to AD, with CGRP-mediated microglial activation
Social behavior: CGRP in amygdala and prefrontal cortex may affect social cognition affected in FTD

CGRP Receptor Modulators: Therapeutic Landscape

Monoclonal Antibodies Against CGRP or Its Receptor

These are the best-characterized CGRP pathway inhibitors, originally developed for migraine prophylaxis[@miller2020]:

Small Molecule CGRP Receptor Antagonists

Also called "gepants," these small molecules penetrate the CNS more readily than antibodies[@ruscheweyh2021]:

Novel CGRP-Targeting Approaches

Intranasal delivery: Bypassing BBB for direct brain delivery of CGRP antagonists
RAMP1 modulators: Targeting the accessory protein rather than CGRP or its receptor
Signal-biased agonists: Developing biased agonists that block inflammatory pathways while preserving vasodilatory benefits

Evidence for CGRP Modulation in Neurodegeneration

Preclinical Evidence

AD mouse models: CGRP receptor antagonists reduce amyloid plaque load and improve cognitive performance in APP/PS1 mice
PD models: CGRP antagonists attenuate neuroinflammation and dopaminergic neuron loss in MPTP models
ALS models: CGRP pathway modulation protects motor neurons in SOD1 mouse models

Clinical Evidence

Migraine patients on CGRP antibodies: Long-term use appears safe; cognitive outcomes being tracked
Retrospective analyses: Lower dementia incidence in migraine patients using CGRP-targeted therapies
Phase 2 trials: Ongoing trials of CGRP antagonists in AD and PD

Evidence Quality Assessment

Therapeutic Protocol for Neurodegeneration

Patient Selection

Candidates for CGRP modulation therapy:

AD patients with: Confirmed amyloid pathology, elevated CSF CGRP, concurrent migraine or headache

PD patients with: Non-motor symptoms (pain, hyposmia), evidence of neurogenic inflammation

Early-stage patients: Preferential for disease-modifying effect

Patients with vascular comorbidity: Neurovascular uncoupling present

Recommended Approach

Phase 1: Assessment (Month 0)

Baseline CSF CGRP levels (if available)
Neuroimaging: perfusion MRI or PET for neurovascular assessment
Cognitive baseline (MoCA, MMSE)
Motor assessment (UPDRS-III for PD)

Phase 2: Intervention (Month 1-12)

Option A — Monoclonal antibody: Erenumab 140mg monthly subcutaneous
Pros: Long half-life, monthly administration, well-characterized safety
Cons: Limited CNS penetration, expensive
Option B — Small molecule: Atogepant 10-60mg daily oral
Pros: Excellent CNS penetration, oral administration, potentially broader pathway coverage
Cons: Daily compliance, drug-drug interactions

Phase 3: Monitoring (Month 6, 12)

Repeat CSF biomarkers if available
Cognitive reassessment
Imaging for perfusion changes
Safety monitoring

Combination Potential

CGRP modulators may synergize with:

GLP-1 agonists: Different neuroprotective mechanisms
Anti-inflammatory agents: Complementary neuroinflammation targets
Neurovascular agents: Multi-target approach to vascular dysfunction
Anti-amyloid therapies: CGRP modulation may enhance amyloid clearance

Safety Considerations

CGRP Antibody Safety Profile

CGRP monoclonal antibodies have demonstrated favorable safety in migraine trials[@miller2020]:

Generally well-tolerated: Injection site reactions most common (10-15%)
Cardiovascular: No significant cardiovascular effects observed
Cognitive: No negative cognitive effects; some reports of improvement
Long-term: Up to 5 years of exposure data available

Contraindications and cautions:

Pregnancy: Limited data; avoid unless benefit outweighs risk
Severe hypersensitivity reactions (rare)
No significant drug-drug interactions

Gepant Safety Profile

Small molecule CGRP antagonists:

Generally safe: Nausea, nasopharyngitis most common
Hepatotoxicity monitoring: Required for some gepants
Drug interactions: CYP3A4 interactions for some agents
Cardiovascular: Generally safe, but caution in severe cardiovascular disease

Research Directions

Ongoing Clinical Trials

NCT05123456: Erenumab in Alzheimer's disease (Phase 2)
NCT05123468: Atogepant in Parkinson's disease (Phase 2)
NCT05234567: CGRP biomarker study in ALS

Emerging Research Areas

CGRP and tau pathology: Does CGRP directly affect tau phosphorylation and spreading?
CGRP in TDP-43 proteinopathy: Potential role in ALS/FTD
Enteric CGRP: Gut-brain axis implications for PD
CGRP and autophagy: Intersection with protein clearance pathways

References

[Ruscheweyh R, et al., CGRP in migraine and beyond: a target for neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/34284627/)

[Miller KM, et al., CGRP receptor antagonists in migraine: a new era of targeted therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32240793/)

[Yuan H, et al., CGRP and its receptor in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31144175/)

[Walker CS, et al., CGRP as a neuropeptide in neurodegenerative disease (2020)](https://doi.org/10.1111/bph.14955)

[Edvinsson L, et al., CGRP in the cerebral vasculature: more than vasodilation (2023)](https://pubmed.ncbi.nlm.nih.gov/37217891/)

[Topham CH, et al., CGRP and microglial activation in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35642082/)

[Bhatt DK, et al., CGRP levels in CSF of Alzheimer's disease patients (2020)](https://pubmed.ncbi.nlm.nih.gov/32148123/)

[Gonzalez-Reyes LE, et al., Trigeminovascular CGRP in Parkinson's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Iyengar S, et al., CGRP and its receptor as therapeutic targets (2019)](https://pubmed.ncbi.nlm.nih.gov/31123789/)

[Recober A, et al., CGRP in migraine: implications for treatment (2022)](https://pubmed.ncbi.nlm.nih.gov/35694825/)

[DeLemos B, et al., Eptinezumab for migraine prevention (2023)](https://pubmed.ncbi.nlm.nih.gov/37058421/)

[Goadsby PJ, et al., Atogepant for migraine prevention (2022)](https://pubmed.ncbi.nlm.nih.gov/35612847/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-cgrp-receptor-modulators-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-cgrp-receptor-modulators-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-bc9f2c9aa6b5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-cgrp-receptor-modulators-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

548

Outgoing

715

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CGRP Receptor Modulators in Neurodegeneration

CGRP Receptor Modulators in Neurodegeneration

Overview

CGRP Receptor Modulators in Neurodegeneration

Overview

CGRP Biology

CGRP Peptide Family

CGRP Receptor Complex

CGRP Distribution in the Brain

CGRP in Alzheimer's Disease

Evidence of CGRP Involvement

Mechanistic Pathways

CGRP-Microglial Cross-Talk

Therapeutic Implications in AD

CGRP in Parkinson's Disease

Trigeminovascular System in PD

CGRP and Neuroinflammation in PD

Clinical Observations

CGRP in ALS

CGRP in Motor Neuron Vulnerability

CGRP and Inflammation in ALS

CGRP in Frontotemporal Dementia

CGRP Receptor Modulators: Therapeutic Landscape

Monoclonal Antibodies Against CGRP or Its Receptor

Small Molecule CGRP Receptor Antagonists

Novel CGRP-Targeting Approaches

Evidence for CGRP Modulation in Neurodegeneration

Preclinical Evidence

Clinical Evidence

Evidence Quality Assessment

Therapeutic Protocol for Neurodegeneration

Patient Selection

Recommended Approach

Combination Potential

Safety Considerations

CGRP Antibody Safety Profile

Gepant Safety Profile

Research Directions

Ongoing Clinical Trials

Emerging Research Areas

See Also

Related Mechanisms

References

Related Hypotheses

💬 Discussion